Chen Jaime, Xu Ronghui, Hunt Gordon C, Krinsky Mary Lee, Savides Thomas J
Division of Gastroenterology, Department of Internal Medicine, University of California, San Diego, and Department of Internal Medicine, San Diego Veterans Affairs Hospital, California, USA.
Clin Gastroenterol Hepatol. 2006 May;4(5):573-9. doi: 10.1016/j.cgh.2006.01.006.
BACKGROUND & AIMS: The nodal staging of esophageal cancer accounts for the absence or presence of metastatic lymph nodes (N0 or N1, respectively). Surgical data suggest that patients have worse survival when esophagectomy specimens contain higher numbers of regional malignant lymph nodes. It has been proposed that the staging system for esophageal cancer be modified to include the number of malignant lymph nodes. The aim of this study was to determine the influence of the number of malignant-appearing regional lymph nodes detected on endoscopic ultrasonography (EUS) on survival in patients with esophageal adenocarcinoma.
Historical case series involved patients with esophageal adenocarcinoma who underwent EUS staging at a single center between 1994 and 2004. Endoscopy reports were reviewed to determine the number of malignant-appearing periesophageal lymph nodes seen on EUS examination. Subjects were categorized as having 0, 1-2, or >2 periesophageal lymph nodes. A regional cancer registry prospectively obtained survival data.
Among 85 patients with esophageal adenocarcinoma, the Kaplan-Meier curves showed distinct survival advantages in those with fewer malignant-appearing regional lymph nodes (P=.0008). The median survivals were 66 months, 14.5 months, and 6.5 months for 0, 1-2, and >2 malignant-appearing lymph nodes, respectively. Survival was also influenced by celiac lymph nodes and tumor length, both of which were associated with increased number of malignant nodes.
The number of malignant-appearing periesophageal lymph nodes detected by EUS is associated with improved survival stratification in patients with esophageal adenocarcinoma and should be considered in the presurgical staging of esophageal cancer.
食管癌的淋巴结分期取决于有无转移性淋巴结(分别为N0或N1)。手术数据表明,食管切除标本中区域恶性淋巴结数量较多的患者生存率较低。有人提议修改食管癌分期系统,纳入恶性淋巴结数量。本研究的目的是确定内镜超声检查(EUS)发现的区域恶性淋巴结数量对食管腺癌患者生存率的影响。
回顾性病例系列研究纳入了1994年至2004年间在单一中心接受EUS分期的食管腺癌患者。查阅内镜报告,确定EUS检查中所见的食管周恶性淋巴结数量。将受试者分为食管周淋巴结数量为0、1 - 2或>2组。区域癌症登记处前瞻性获取生存数据。
在85例食管腺癌患者中,Kaplan-Meier曲线显示区域恶性淋巴结数量较少的患者具有明显的生存优势(P = .0008)。食管周恶性淋巴结数量为0、1 - 2和>2时的中位生存期分别为66个月、14.5个月和6.5个月。生存还受腹腔淋巴结和肿瘤长度的影响,这两者均与恶性淋巴结数量增加有关。
EUS检测到的食管周恶性淋巴结数量与食管腺癌患者的生存分层改善相关,应在食管癌术前分期中予以考虑。